A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

• Status: RECRUITING
• Trial end date: 2026-12-30

Summary

This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung cancer (ES-SCLC) in the first-line (1L) setting.

• Phase: PHASE1

Details

• Lead Sponsor: Daiichi Sankyo
• Collaborator: Merck Sharp & Dohme LLC
• Treatments: atezolizumab; Carboplatin